Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577512 · ClinicalTrials.gov registry record · Phase 2
2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
A Phase 2 study of Multiple Myeloma, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT00577512: Completed Phase 2 study of Multiple Myeloma, sponsored by University of Arkansas.
NCT00577512 is a Phase 2 study of Multiple Myeloma that has completed, run by University of Arkansas. The registered enrollment target is 4 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00577512, a Phase 2 study of Multiple Myeloma, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses closer together (before the myeloma comes back or gets worse), subjects in this study will have better outcomes.
Primary Outcome
Complete Response (CR) defined as all of the following for a minimum of 2 months: a) absence of urine and serum M-components by immunofixation; b) bone marrow should be adequately cellular (\>20%); c) normal serum calcium; d) no new bone lesions or enlargement of existing lesions. Near Complete Response included all elements of CR except immunofixation studies remained positive.
Conditions Studied
Interventions
- DRUG DTPACE
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
What the finished NCT00577512 record still lists
NCT00577512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which DTPACE is the first listed.
NCT00577512 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT00577512 about?
NCT00577512 is a clinical study titled "2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE". This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses closer together (before the myeloma comes back or gets worse), subjects in...
What is the current status of trial NCT00577512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2007-04. Estimated completion is 2009-04.
What conditions does trial NCT00577512 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00577512?
The interventions under investigation include: DTPACE (DRUG).
Who is sponsoring clinical trial NCT00577512?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00577512 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00577512's enrollment target sits among peer trials
4 435th of 438 higher than 2 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia